SCHEMBL5532202

SCHEMBL5532202

CC#Cc1ccc(NC(=O)c2ccccc2N(C=O)c2ccc(C=NN(C)C)cc2)nc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.33
NPC1 O15118 5/20 0.33
RAB9A P51151 5/20 0.33
TP53 P04637 4/20 0.33
ALDH1A1 P00352 3/20 0.33
F10 P00742 3/20 0.33
GAA P10253 3/20 0.33
KDM4E B2RXH2 2/20 0.33
FGFR4 P22455 1/20 0.33
ALOX15 P16050 1/20 0.33
HTT P42858 1/20 0.33
GLA P06280 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPK1 P28482 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.32
LMNA P02545 3/20 0.32
MAPT P10636 3/20 0.32
TDP1 Q9NUW8 1/20 0.31
POLB P06746 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534774 0.90 FGFR4 (0.43) SMN1; SMN2NPC1RAB9ATP53ALDH1A1
SCHEMBL5535939 0.86 RAB9A (0.32) SMN1; SMN2NPC1RAB9ATP53ALDH1A1
SCHEMBL5533696 0.79 F10 (0.49) NPC1RAB9AF10FGFR4ALOX15
SCHEMBL5531693 0.78 FGFR4 (0.38) SMN1; SMN2NPC1RAB9ATP53ALDH1A1
SCHEMBL5534106 0.77 F10 (0.42) SMN1; SMN2NPC1RAB9AALDH1A1F10
SCHEMBL5530778 0.76 FGFR4 (0.42) SMN1; SMN2NPC1RAB9ATP53ALDH1A1
SCHEMBL5553907 0.75 F10 (0.47) SMN1; SMN2NPC1RAB9ATP53ALDH1A1
SCHEMBL890764 0.75 F10 (0.49) SMN1; SMN2NPC1RAB9AF10KDM4E
SCHEMBL5534849 0.72 F10 (0.47) F10FGFR4SIRT2TMPRSS4
SCHEMBL5536431 0.71 F10 (0.46) F10FGFR4SIRT2TMPRSS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP claimed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP disclosed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US disclosed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 SMN1; SMN2 2492/4885NPC1 2635/4885RAB9A 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.